Clinical trials: Helicobacter Pylori Infections
Helicobacter Pylori
A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
The purpose of this study is to evaluate the efficacy of helicobacter pylori (HP) eradication with bismuth-containing quadruple therapy with vonoprazan versus esomeprazole in all HP-positive participants.
- Trial name
- NCT04198363
- Testing
- Vonoprazan, Amoxicillin, Clarithromycin
- Where
- 29 sites in China
- Volunteers
- 510 people
- Sponsor
- Takeda
Helicobacter Pylori Infection, Post-Treatment
PyloPlus Urea Breath Test System Post Therapy Efficacy Confirmation Study
This is a multi-center, non-randomized, open label study. Subjects will be enrolled if they are deemed eligible given the inclusion criteria.
- Conditions
- Helicobacter Pylori Infection, Post-Treatment, Efficacy
- Trial name
- NCT05681689
- Testing
- PyloPlus UBT System, Histology, Rapid Urease Test
- Where
- 2 sites in United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- ARJ Medical, Inc.
Helicobacter Pylori Infection
Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication
Today, although the triple treatment with clarithromycin accepted as the primary treatment for Helicobacter pylori infection eradication is well tolerated, the eradication has been decreased to 65 %.
- Trial name
- NCT01131026
- Testing
- Levofloxacin, Amoxicillin, Lansoprazole
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Deva Holding A.S.
Helicobacter Pylori
A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
The main aim of the study is to review treatment therapies in people with Helicobacter pylori (H. pylori) infections in standard hospital settings in China.
- Trial name
- NCT05073367
- Where
- 5 sites in China
- Volunteers
- 23,000 people
- Sponsor
- Takeda
Helicobacter Pylori Infection
10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection
Helicobacter pylori (H. pylori) infection is highly associated with gastrointestinal disorders, including peptic ulcer disease, gastric cancer, and gastric mucosa associated lymphoid tissue lymphoma.1 In 1994, H.
- Trial name
- NCT02959255
- Testing
- Esomeprazole
- Where
- Greece
- Volunteers
- 364 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Gastric Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with gastric ulcer.
- Trial name
- NCT03050307
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 234 people
- Sponsor
- Takeda
Erosive Gastritis, Erosive Esophagitis(EE)
Bioequivalence Study to Compare Vonoprazan 20 mg Film Coated Tablets Versus Voquezna® 20 mg (Vonoprazan) Tablets
Randomized, Single Dose, Two-Way Crossover, Open Label bioequivalence study to compare Vonoprazan 20 mg Film Coated Tablets versus Voquezna® 20 mg (Vonoprazan) Tablets an oral administration to healthy adults under fasting…
- Conditions
- Erosive Gastritis, Erosive Esophagitis(EE), HELICOBACTER PYLORI INFECTIONS
- Trial name
- NCT07278349
- Testing
- Vonoprazan Tablets, VOQUEZNA® Tablets
- Where
- Jordan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Helicobacter Infections, Urinary Tract Infection
First Time in Man Study of Finafloxacin Hydrochloride
The purpose of this study is to study the safety of single doses and multiple doses of Finafloxacin hydrochloride in healthy volunteers. The level of Finafloxacin hydrochloride will be measured in the subjects blood and urine.
- Trial name
- NCT00483158
- Testing
- Finafloxacin hydrochloride
- Where
- Switzerland
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- MerLion Pharmaceuticals GmbH
Helicobacter Pylori Infection
Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection
The Exalenz Dual Mode BreathID® Hp System comprised of IDkit: Hp™ TWO and the Dual Mode BreathID® Hp test device will be used to perform a urea breath test in the initial diagnosis and post treatment monitoring of H.pylori…
- Trial name
- NCT02528721
- Testing
- Dual Mode BreathID Hp System
- Where
- 13 sites in United States, Israel
- Volunteers
- 282 people
- Sponsor
- Meridian Bioscience, Inc.
Helicobacter Pylori Infection
Efficacy and Safety of Lacidofil® STRONG as an Adjuvant for Helicobacter Pylori Treatment in Non-ulcer Dyspepsia
Treatment for H. pylori eradication includes antibiotics. The treatment has decreased its efficiency (lower capability to eradicate the infection) due to increasing antibiotic resistance in the population.
- Trial name
- NCT04473079
- Testing
- Lacidofil
- Where
- Thailand
- Volunteers
- 90 people
- Sponsor
- Lallemand Health Solutions
Helicobacter Pylori Infection
Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori
The purpose of this study is to evaluate the effect of Pylera when given twice a day. Pylera approved treatment schedule is 3 pills taken 4 times daily, in addition to omeprazole given twice daily.
- Trial name
- NCT00712413
- Testing
- OBMT
- Where
- 3 sites in United States, Canada
- Sponsor
- Forest Laboratories
Helicobacter Pylori
Optimized-dose Amoxicillin Versus Standard-dose Amoxicillin for Quadruple Therapy in Helicobacter Pylori Eradication
The goal of this prospective randomized clinical trial is to compare the rate of Helicobacter Pylori (HP) eradication after standard or dose-optimized amoxicillin quadritherapy in patients naïve to any anti-HP treatment and with…
- Trial name
- Helicomatri (NCT05635942)
- Testing
- optimized quadruple therapy, standard quadruple therapy
- Where
- Tunisia
- Volunteers
- 88 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Helicobacter Pylori Infection
Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults
To study the safety, immunogenicity and efficacy of an investigational H. pylori vaccine, compared with placebo.
- Trial name
- NCT00736476
- Testing
- H.pylori vaccines
- Where
- Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
HELICOBACTER INFECTION
Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion
Helicobator pylori (H. pylori) is a bacteria which survives in the lining of the stomach. An estimated 50% of the world's population is infected with H. pylori.
- Trial name
- NCT02051348
- Testing
- Pylopass
- Where
- Ireland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Atlantia Food Clinical Trials
Helicobacter Pylori Infection, Dyspepsia
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H.
- Trial name
- ERADICATE Hp2 (NCT03198507)
- Testing
- RHB-105, Active Comparator
- Where
- 55 sites in United States
- Volunteers
- 455 people
- Sponsor
- RedHill Biopharma Limited
Helicobacter Infections
Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
This study aims at evaluating efficacy and safety of quadruple therapy (bismuth, metronidazole, tetracycline and omeprazole: OBMT) vs triple therapy (amoxicillin, clarithromycin and omeprazole: OAC) in H. Pylori eradication.
- Trial name
- NCT00669955
- Testing
- Omeprazole, amoxicillin, clarithromycin, Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole
- Where
- United Kingdom
- Volunteers
- 440 people
- Sponsor
- Forest Laboratories
Helicobacter Pylori Infection
A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients
This study compared efficacy and safety of basic triple therapy according to treatment period. This study evaluated Effect of CYP2C19 genetic polymorphisms on the efficacy
- Trial name
- NCT03099876
- Testing
- treatment period
- Where
- 4 sites in South Korea
- Volunteers
- 320 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Helicobacter Pylori Infection
13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
Approximately 200 patients with suspected H.pylori will be tested with a 13C-Urea Breath Test (UBT) to ascertain H.pylori positive.
- Trial name
- NCT00825630
- Testing
- Lansoprazole (Lanton), Omeprezole (Losec), Pantoprazole(Controloc)
- Where
- Israel
- Volunteers
- 123 people
- Sponsor
- Meridian Bioscience, Inc.
Suspicion of Being Infected With H.Pylori
Show Equivalence of the Modified BreathID Compared to Currently Approved BreathID in H.Pylori Detection
The purpose of this study is to confirm equivalence of a new generation breath analyzer (Modified BreathID) in its ability to detect H. pylori compared to the currently approved BreathID® System.
- Trial name
- NCT01650831
- Testing
- Modified BreathID
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Meridian Bioscience, Inc.
H. Pylori Infection
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
The purpose of this study is to confirm the efficacy of triple therapy with TAK-438, Amoxicillin and Clarithromycin, twice daily (BID) by demonstrating its non-inferiority to triple therapy with Lansoprazole, Amoxicillin and…
- Trial name
- NCT01505127
- Testing
- TAK-438, Lansoprazole, Amoxicillin
- Where
- 35 sites in Japan
- Volunteers
- 650 people
- Sponsor
- Takeda